## Yung Lyou

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9192756/publications.pdf

Version: 2024-02-01

23 papers	1,087 citations	933447 10 h-index	22 g-index
23	23	23	1701 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Global Reorganization of Replication Domains During Embryonic Stem Cell Differentiation. PLoS Biology, 2008, 6, e245.	5.6	496
2	Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine, 2022, 28, 704-712.	30.7	181
3	Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer & Metabolism, 2016, 4, 20.	<b>5.</b> O	63
4	Generation of Functional Eyes from Pluripotent Cells. PLoS Biology, 2009, 7, e1000174.	5 <b>.</b> 6	60
5	Machine Learning–Based Interpretation and Visualization of Nonlinear Interactions in Prostate Cancer Survival. JCO Clinical Cancer Informatics, 2020, 4, 637-646.	2.1	52
6	Inhibition of nuclear Wnt signalling: challenges of an elusive target for cancer therapy. British Journal of Pharmacology, 2017, 174, 4589-4599.	5.4	48
7	Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis., 2020, 8, e000953.		32
8	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. JAMA Oncology, 2021, 7, 1536.	7.1	28
9	Wnt∫β-Catenin Signaling and Immunotherapy Resistance: Lessons for the Treatment of Urothelial Carcinoma. Cancers, 2021, 13, 889.	3.7	24
10	Maturin is a novel protein required for differentiation during primary neurogenesis. Developmental Biology, 2013, 384, 26-40.	2.0	21
11	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 916-924.	1.9	18
12	Advances in Immunotherapy and the TGF-Î <sup>2</sup> Resistance Pathway in Metastatic Bladder Cancer. Cancers, 2021, 13, 5724.	3.7	13
13	Radiation-Associated Angiosarcoma of the Breast: A Case Report and Literature Review. Case Reports in Oncology, 2018, 11, 216-220.	0.7	10
14	Managing Bladder Cancer Care during the COVID-19 Pandemic Using a Team-Based Approach. Journal of Clinical Medicine, 2020, 9, 1574.	2.4	9
15	Disruption of β-Catenin–Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion. Molecular Cancer Research, 2022, 20, 468-484.	3.4	7
16	Hormonal manipulation in androgen signaling: a narrative review on using novel androgen therapy agents to optimize clinical outcomes and minimize side effects for prostate cancer patients.  Translational Andrology and Urology, 2021, 10, 3199-3207.	1.4	6
17	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 31-38.	2.2	5
18	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 35-42.	1.9	5

## Yung Lyou

#	Article	IF	CITATION
19	A Patient with Supraclavicular Lymphadenopathy and Anterior Mediastinal Mass Presenting as a Rare Case of Composite Lymphoma: A Case Report and Literature Review. Case Reports in Oncology, 2017, 9, 854-860.	0.7	2
20	Disseminated Microinfarctions with Cerebral Microbleeds. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, e95-e97.	1.6	2
21	Orbital Metastases from Breast Cancer with BRCA2 Mutation: A Case Report and Literature Review. Case Reports in Oncology, 2018, 11, 360-364.	0.7	2
22	Prostate Cancer Characteristics and Outcomes after Prostatectomy in Asian-American Men. Clinical Genitourinary Cancer, 2022, 20, 92-92.e6.	1.9	2
23	Defining Value in Metastatic Prostate Cancer: What Is the Cost of Living Longer and Better?. JCO Oncology Practice, 2020, 16, 53-54.	2.9	1